Current strategies against multi-drug resistant organisms;Multiresistente Erreger - Infektionsmanagement 2015

Deutsche Medizinische Wochenschrift

Volumn 140, Issue 13, 2015, Pages 975-981

  Pletz, Mathias W ^a   Eckmann, Christian ^b   Hagel, Stefan ^a   Heppner, Hans Jürgen ^c   Huber, Kora ^d   Kämmerer, Wolfgang ^e   Schmitz, Franz Josef ^f   Wilke, Michael ^g   Grabein, Béatrice ^h  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Klinikum Peine   (Germany)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

^d Consultant Infektiologie ^*  (Germany)

^e KLINIKUM AUGSBURG   (Germany)

^f KLINIKUM MINDEN   (Germany)

^g Dr Wilke GmbH Inspiringhealth   (Germany)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antibiotic Stewardship; deescalation therapy; ESKAPE; multi drug resistant organism

Indexed keywords

ARTICLE; MULTIDRUG RESISTANCE; BACTERIAL INFECTIONS; COMBINATION DRUG THERAPY; COST OF ILLNESS; CROSS INFECTION; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

ANTIINFECTIVE AGENT; COLISTIN;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COLISTIN; COST OF ILLNESS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 84933060417     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0041-102452     Document Type: Article

References (37)

1. Kumar A., Roberts D., Wood K. E. et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med: 2006; 34 1589 1596
2. Lodise T. P. Jr, McKinnon P. S., Levine D. P., Rybak M. J. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother: 2007; 51 3731 3733
3. Owens R. C. Jr. Antimicrobial stewardship: concepts and strategies in the 21st century. Diagn Microbiol Infect Dis: 2008; 61 110 128
4. Paterson D. L. Collateral damage from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis: 2004; 38 04 S341 S345
5. Boucher H. W., Talbot G. H., Bradley J. S. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis: 2009; 48 1 12
6. Cardoso T., Ribeiro O., Aragao I. C. et al. Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection: a large cohort study. BMC Infect Dis: 2012; 12 375
7. Peterson L. R. Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis: 2009; 49 992 993
8. Fernandez-Cruz A., Eworo A., Alcalá L. et al. Delay in Administration of Adequate Antimicrobial Therapy Correlates with a Worse Prognosis in an Unselected Population with Bloodstream Infection (BSI). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco American Society for Microbiology: 2009; K-257
9. Von Baum H., Kaase M., Meyer E. et al. Definition der Multiresistenz gegenüber Antibiotika bei gramnegativen Stäbchen im Hinblick auf Maβnahmen zur Vermeidung der Weiterverbreitung. Epidemiologisches Bulletin: 2011; 337 339
10. Woerther P. L., Burdet C., Chachaty E., Andremont A. Trends in human fecal carriage of extended-spectrum beta-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev: 2013; 26 744 758
11. Lubbert C., Straube L., Stein C. et al. Colonization with extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany. Int J Med Microbiol: 2015; 305 148 156
12. Stocker H., Kern W. V. Colistin. Internist (Berl): 2013; 54 936 944
13. Anthony K. B., Fishman N. O., Linkin D. R. et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Diss: 2008; 46 567 570
14. Becker K., Kriegeskorte A., Sunderkotter C. et al. Chronisch rezidivierende Infektionen der Haut und Weichgewebe durch Staphylococcus aureus. Der Hautarzt: 2014; 65 15 25
15. Loffler B., Niemann S., Ehrhardt C. et al. Pathogenesis of Staphylococcus aureus necrotizing pneumonia: the role of PVL and an influenza coinfection. Expert Rev Anti Infect Ther: 2013; 11 1041 1051
16. Layer F., Werner G. Eigenschaften, Häufigkeit und Verbreitung von MRSA in Deutschland - Update 2011/2012. Epidemiologisches Bulletin: 2013; 187 192
17. Welte T., Pletz M. W. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents: 2010; 36 391 400
18. Gastmeier P., Schroder C., Behnke M. et al. Dramatic increase in vancomycin-resistant enterococci in Germany. J Antimicrob Chemother: 2014; 69 1660 1664
19. Solomkin J. S., Mazuski J. E., Bradley J. S. et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis: 2010; 50 133 164
20. Bodmann K. F., Grabein B. und die Expertenkommission der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Hrsg. Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2010. Rheinbach: 2010
21. Dalhoff K., Abele-Horn M., Andreas S. et al. Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie. Pneumologie: 2012; 66 707 765
22. Eckmann C., Dryden M., Montravers P. et al. Antimicrobial treatment of complicated intra-abdominal infections and the new IDSA guidelines a commentary and an alternative European approach according to clinical definitions. Eur J Med Res: 2011; 16 115 126
23. Eckmann C., Montravers P., Bassetti M. et al. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother: 2013; 68 02 ii25 ii35
24. Balli E. P., Venetis C. A., Miyakis S. Systematic Review and Meta-Analysis of Linezolid versus Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bacteremia. Antimicrob Agents Chemother: 2014; 58 734 739
25. Kuijper E. J., Wilcox M. H. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection Clin Infect Dis: 2008; 47 63 65
26. Debast S. B., Bauer M. P., Kuijper E. J. et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect: 2014; 20 02 1 26
27. Louie T. J., Miller M. A., Mullane K. M. et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med: 2011; 364 422 431
28. Cornely O. A., Nathwani D., Ivanescu C. et al. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother: 2014; 69 2892 2900
29. Herpers B. L., Vlaminckx B., Burkhardt O. et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis: 2009; 48 1732 1735
30. El-Herte R. I., Baban T. A., Kanj S. S. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. Scand J Infect Dis: 2012; 44 228 230
31. de With K., Allerberger F., Armann S. et al. S3-Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. 2013; (AWMF-Registriernummer 092/001)
32. Schwaber M. J., Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother: 2007; 60 913 920
33. Kämmerer W. Klinisch relevante pharmakokinetische Arzneimittelinteraktionen in der Intensivmedizin. Intensivmedizin und Notfallmedizin: 2011; 48 480 492
34. Schindler A., Wilke M. Finanzierung und Entgeltsystem 2013. Erreger im Keim ersticken. Führen und Wirtschaften im Krankenhaus: 2013; 3 288 292
35. European Centre for Disease Prevention and Control Antimicrobial resistance interactive database. http://www.ecdc.europa.eu/en/healthtopics/antimicrobial-resistance/database/Pages/database.aspx Letzter Zugriff am 18.05.2015
36. Robert Koch-Institut Kommission Antiinfektiva, Resistenz und Therapie 2013. http://www.rki.de/DE/Content/Kommissionen/ART/ART-node.htm Letzter Zugriff am 19.05.2015
37. Tumbarello M., Viale P., Viscoli C. et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis: 2012; 55 943 950